NASDAQ
07.01.25
15:30 Uhr
1,650 US-Dollar
-0,050
-2,94 %
-2,94 %
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | BeyondSpring Inc. - 8-K, Current Report | - | SEC Filings | ||
| 11.11.24 | BeyondSpring, Inc.: BeyondSpring Presents Updated Efficacy Results from a Phase 2 IIT Study of Triple IO Combo of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on Prior ... | 106 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Nov. 11, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| BEYONDSPRING Aktie jetzt für 0€ handeln | |||||
| 16.09.24 | BeyondSpring plinabulin, Merck Keytruda combo shows promise in NSCLC | 4 | Seeking Alpha | ||
| 16.09.24 | BeyondSpring berichtet über sicherere Therapieoption für NSCLC | 1 | Investing.com Deutsch | ||
| 16.09.24 | BeyondSpring reports safer NSCLC therapy option | 10 | Investing.com | ||
| 16.09.24 | BeyondSpring reports promising phase 2 NSCLC study results | 10 | Investing.com | ||
| 16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Efficacy/Safety Results from a Phase 2 Study of Pembrolizumab plus Plinabulin/Docetaxel in Metastatic NSCLC after Progressing on First-Line Immune Checkpoint Inhibitors at ESMO Congress 2024 | 137 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 16.09.24 | BeyondSpring, Inc.: BeyondSpring Presents Final Data Analysis of DUBLIN-3 Phase 3 Study in 2L/3L EGFR Wild-type NSCLC at ESMO Congress 2024 | 128 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company developing innovative cancer... ► Artikel lesen | |
| 03.09.24 | BeyondSpring, Inc.: BeyondSpring Announces Oral Presentation at the 2024 World Conference on Lung Cancer and Two Poster Presentations During ESMO Congress 2024 Showcasing its Lead Anti-Cancer Asset, Plinabulin | 1 | GlobeNewswire (USA) | ||
| 29.08.24 | BeyondSpring Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.08.24 | BeyondSpring Inc. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 06.08.24 | BeyondSpring, Inc.: SEED Therapeutics (SEED) Enters into Strategic Research Collaboration with Eisai Co., Ltd. to Discover and Develop Novel Molecular Glue Degraders for Neurodegeneration and Oncology Indications | 180 | GlobeNewswire (Europe) | The SEED-Eisai Research Collaboration leverages Eisai's leading expertise in neurodegeneration and cancer. SEED is entitled to receive upfront and milestone payments of up to $1.5 billion plus tiered... ► Artikel lesen | |
| 29.04.24 | BeyondSpring, Inc.: BeyondSpring Provides Business Update and Reports Year End 2023 Financial Results | 190 | GlobeNewswire (Europe) | - BeyondSpring Dosed First Patient of Two Phase 2 Investigator-Initiated Trials (IIT) in Plinabulin and Keytruda Combination Studies - SITC 2023 Presentation of the Phase 1 Topline Clinical and Mechanism... ► Artikel lesen | |
| 25.03.24 | BeyondSpring, Inc.: BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer | 92 | GlobeNewswire (Europe) | FLORHAM PARK, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a clinical-stage global biopharmaceutical company focused on developing innovative... ► Artikel lesen | |
| 10.01.24 | BeyondSpring, Inc.: BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K | 106 | GlobeNewswire (Europe) | NEW YORK, Jan. 10, 2024 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ: BYSI) ("BeyondSpring" or the "Company"), a global clinical-stage biopharmaceutical company focused on using a groundbreaking... ► Artikel lesen |
15 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SANA BIOTECHNOLOGY | 4,290 | 0,00 % | Sana Biotechnology, Inc: Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression | First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate... ► Artikel lesen | |
| VIR BIOTECHNOLOGY | 12,450 | 0,00 % | Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why | ||
| QUANTUM-SI | 2,640 | 0,00 % | Behind the Scenes of Quantum-Si's Latest Options Trends | ||
| KYMERA THERAPEUTICS | 40,520 | 0,00 % | Analysts Issue Forecasts for KYMR FY2029 Earnings | ||
| HUMACYTE | 4,680 | -1,27 % | Pre-market Movers: My Size, Nvni Group, Psyence Biomedical, Humacyte, PainReform | BRASILIA (dpa-AFX) - The following are some of the stocks making big moves in Friday's pre-market trading (as of 07.55 A.M. ET).In the Green My Size, Inc. (MYSZ) is up over 372% at $6.43.
Nvni... ► Artikel lesen | |
| TEMPUS AI | 37,470 | 0,00 % | COO von Tempus AI, Ryan Fukushima, verkauft Aktien im Wert von 792.191 US-Dollar | ||
| PRAXIS PRECISION MEDICINES | 73,68 | -4,95 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Announces Rare Pediatric Disease Designation Granted for Relutrigine in Dravet Syndrome | Dravet syndrome is a genetic developmental and epileptic encephalopathy (DEE) often caused by a mutation in SCN1A This is the third Rare Pediatric Disease Designation for relutrigine, adding to those... ► Artikel lesen | |
| VERA THERAPEUTICS | 42,190 | +0,21 % | Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | BRISBANE, Calif., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vera Therapeutics, Inc. (Nasdaq: VERA) today announced that on December 3, 2024, the Compensation Committee granted inducement awards consisting... ► Artikel lesen | |
| RELAY THERAPEUTICS | 4,830 | 0,00 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Updated Interim Data for RLY-2608 + Fulvestrant Demonstrating Continued Maturation of Clinically Meaningful Progression Free Survival | New interim data show 11.4-month median PFS in 2L patients with PI3Ka-mutated, HR+/HER2- metastatic breast cancer at RP2D 39% confirmed ORR across all patients & 67% in patients with kinase mutations... ► Artikel lesen | |
| COGENT BIOSCIENCES | 8,110 | 0,00 % | Cogent Biosciences (NASDAQ:COGT) Shares Up 8.8% - Still a Buy? | ||
| SILO PHARMA | 1,710 | 0,00 % | Silo Pharma, Inc.: Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain | IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing first animal studies SARASOTA, FL, Jan. 02, 2025 (GLOBE... ► Artikel lesen | |
| JANUX THERAPEUTICS | 50,50 | 0,00 % | Pre-market Movers: Cheetah Net Supply Chain Service, NLS Pharmaceutics, PSQ Holdings, Janux Therapeutics, Coherus BioSciences | CANBERA (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.45 A.M. ET).In the Green Cheetah Net Supply Chain Service Inc. (CTNT) is up... ► Artikel lesen | |
| ABSCI | 3,255 | 0,00 % | Absci Corporation: Absci and AMD Announce Collaboration and Strategic Investment to Accelerate the Future of AI Drug Discovery | VANCOUVER, Wash., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Absci Corporation (NASDAQ: ABSI), a data-first generative AI drug creation company, today announced a strategic collaboration with AMD to deploy... ► Artikel lesen | |
| DISC MEDICINE | 62,54 | +0,87 % | Disc Medicine Inc: Disc Medicine Presents Positive Updated Results from Phase 1b Trial in Patients with Myelofibrosis (MF) and Anemia in an Oral Presentation at the 66th American Society of Hematology (ASH) Annual Meeting | Demonstrated durable hematologic response across all patient subgroups, regardless of baseline transfusion status and concomitant JAK inhibitor therapyPhase 2 study in MF anemia has been initiated... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 7,265 | 0,00 % | Recursion Pharmaceuticals: Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More | REC-3565 is a potential best-in-class MALT1 inhibitor for multiple hematology indications, designed to reduce the risk of hyperbilirubinemia, a common side effect of other MALT1 inhibitorsREC-4539... ► Artikel lesen |
Das Unternehmen BEYONDSPRING INC kann der Branche Biotechnologie zugeordnet werden. Die relative Kursveränderung beträgt aktuell -2,94 % bei einem Aktienkurs von 1,650 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BEYONDSPRING INC finden Sie auf Wallstreet Online.
